


END2025



GLYCEMIC OUTCOMES OF DIAZOXIDE CHOLINE EXTENDED-RELEASE (DCCR) TABLETS ADMINISTERED FOR HYPERPHAGIA IN INDIVIDUALS WITH PRADER-WILLI SYNDROME OVER 4 YEARS

ASHLEY H. SHOEMAKER, MD, MSCI
VANDERBILT UNIVERSITY MEDICAL CENTER



**ELECTRONIC PRESENTATION
AND
PLAIN LANGUAGE SUMMARY**

Copies obtained through the QR code are for personal use only.

The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society.


INTRODUCTION

- Prader-Willi syndrome (PWS) is a rare genetic neurobehavioral metabolic disorder, characterized by hyperphagia, accumulation of excess fat, hypotonia, and behavioral / psychological complications.^{1,2}
- People living with PWS are at high risk of developing impaired glycemic control and diabetes.
- DCCR is a once-daily, extended-release tablet that provides for stable plasma concentrations and absorption throughout the GI tract.
- DCCR is approved under the brand name VYKAT™ XR. It is the first product approved by the FDA for the treatment of hyperphagia in individuals 4 years and over with PWS.
- We will review glycemic outcomes in clinical trial participants with PWS after long-term DCCR treatment.



1. Butler MG, Miller JL, Forster JL. Curr Pediatr 2019; 15(4):207-244. 2. Miller Rev JL, Lynn CH, Driscoll DC, et al. Am J Med Genet Part A 2011; 155:1040–1049. Photos provided with consent of the caregiver through University of Florida, USA. Abbreviations: PWS, Prader-Willi syndrome; DCCR, diazoxide choline extended-release.

PHASE 3 DCCR PROGRAM



The combined population from C601+C602-OLE includes 125 participants who received DCCR

DEMOGRAPHICS AND BASELINE CHARACTERISTICS (STUDIES C601+C602-OLE)

At Baseline:

- 8.8% took glucose-lowering medications
- Mean (SD) HbA1c% was 5.55 (0.41)
- Mean (SD) fasting glucose (mg/dL) was 90 (11.45)
- 60% had a history of diabetes or prediabetes

DCCR exposure:

- Mean: ~2.5 years
- Median: ~3.0 years
- Maximum: 4.5 years
- 52% exceeded 3 years

DCCR Baseline Characteristics	DCCR-Treated Participants N = 125
Age, years	
Mean (SD)	13.4 (6.98)
Median (range)	12 (4-44)
% Male / % Female	44.8 / 55.2
Race (% White / % Black / % Multiple)	84.8 / 4.8 / 6.4
Weight, mean (SD), kg	62.06 (30.15)
BMI, mean (SD), kg/m ²	27.56 (9.62)
BMI z-score, mean (SD)	1.53 (1.07)
Growth hormone, n (%)	103 (82%)
USA / UK (%)	80.0 / 20.0
HQ-CT total score (0-36), mean (SD)	21.5 (6.70)
PWS subtype	
Deletion, (%)	61.6
Non-deletion, (%)	37.6
Not available, (%)	0.8


Analysis Population (N = 125)

Participants with any TEAE (%)	123 (98.4)
Hyperglycemia-related AE (%)	42 (33.6)
Blood glucose increased (%)	10 (8.0)
Diabetes mellitus (%)	1 (0.8)
Glucose tolerance impaired (%)	1 (0.8)
Hyperglycemia (%)	34 (27.2)
Insulin resistance (%)	2 (1.6)
Type 2 diabetes mellitus (%)	4 (3.2)
Dose changes due to hyperglycemia-related events	n (%)
Any study drug action	19 (15.2)
Discontinuation	2 (1.6)
Dose reduction	10 (8.0)
Dose interruption	8 (6.4)
Concomitant blood glucose-lowering medication initiated (%)	22 (17.6)


GLYCEMIC-RELATED ADVERSE EVENTS

- Adverse events of hyperglycemia were reported by Investigators using a variety of preferred terms.
- Overall, hyperglycemia-related AEs were reported for 33.6% of participants in the analysis population.
- 77.7% of participants remained event-free at 6 months; 63.4% were event-free at 3 years

Time to Onset of First Hyperglycemia-related AE




MEAN (SE) HbA1C OVER TIME




Abbreviations: BL, baseline; SE, standard error; Wk, week.

HbA1c (%) OVER TIME - CATEGORICAL



MEAN (SE) FASTING GLUCOSE OVER TIME



Abbreviations: SE, standard error; Wk, week.

CONCLUSIONS

- **Long-term (~3 years) administration of DCCR for the treatment of hyperphagia in individuals with PWS was generally well tolerated.**
 - Small mean increases observed in HbA1c after DCCR administration. Infrequently associated with clinically significant events.
 - Blood glucose increases typically occurred early, most commonly during titration.
- **Hyperglycemic adverse events were monitorable and generally manageable with standard of care concomitant medications, allowing for continuation of DCCR therapy.**

These findings support a favorable safety profile of DCCR, including consideration of hyperglycemia-related events, in the treatment of hyperphagia in patients with PWS.

ACKNOWLEDGEMENTS

Full author list:

¹Ashley Shoemaker, MD, MSCI, ²Jack A. Yanovski, MD PhD, ^{3,4}Evelien F. Gevers, MD, PhD, ⁵Kathryn Obrynba, MD, ⁶Melissa D. Lah, MD, ⁷Parisa Salehi, MD, ⁸Shuxin Yin, PhD, ⁸Julie Perry, MD, FACOG, ⁸Michael Huang, MD, ⁹Jennifer Miller, MD

¹ Vanderbilt University Medical Center, Nashville, TN, USA. ² Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. ³ Queen Mary University of London, Barts and The London Medical School, William Harvey Research Institute, Centre for Endocrinology, London, United Kingdom. ⁴ Barts Health NHS Trust, Royal London Hospital, London, United Kingdom. ⁵ Nationwide Children's Hospital, Columbus, OH, USA. ⁶ Indiana University School of Medicine, Indianapolis, IN, USA. ⁷ Seattle Children's, Seattle, WA, USA. ⁸ Soleno Therapeutics, Inc., Redwood City, CA, USA. ⁹ University of Florida, Gainesville, FL, USA.

Thank you to our participating Investigators, study sites, study participants and their caregivers in the UK and the USA, as well as the FPWR, PWSA-USA and PWSA-UK!

The authors would also like to acknowledge Jessica Dronen, MSc, for providing medical writing support.